相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma
L. Li et al.
ONCOGENE (2015)
Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles
Raimond Heukers et al.
BIOMATERIALS (2014)
Companion Diagnostics: Has Their Time Come and Gone?
Fred R. Hirsch et al.
CLINICAL CANCER RESEARCH (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors
Elizabeth C. Smyth et al.
ONCOTARGETS AND THERAPY (2014)
Intracellular and extracellular domains of protein tyrosine phosphatase PTPRZ-B differentially regulate glioma cell growth and motility
Annika M. Bourgonje et al.
ONCOTARGET (2014)
Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas
Barbara S. Paugh et al.
CANCER RESEARCH (2013)
Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients
Ning Xia et al.
EXPERIMENTAL LUNG RESEARCH (2013)
The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered
Hui K. Gan et al.
FEBS JOURNAL (2013)
A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction
Sun Tian et al.
GUT (2013)
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2
Anna C. Navis et al.
PLOS ONE (2013)
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
Andrea Sottoriva et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Cell-Autonomous and Non-Cell-Autonomous Mechanisms of HGF/MET-Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective
Simona Corso et al.
CANCER DISCOVERY (2013)
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Alberto Bardelli et al.
CANCER DISCOVERY (2013)
Regulation of HGF Expression by Delta EGFR-Mediated c-Met Activation in Glioblastoma Cells
Jeannine Garnett et al.
NEOPLASIA (2013)
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Kan V. Lu et al.
CANCER CELL (2012)
EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis
Cheng-Bo Han et al.
CANCER LETTERS (2012)
Targeting MET in cancer: rationale and progress
Ermanno Gherardi et al.
NATURE REVIEWS CANCER (2012)
Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
Sai-Hong Ignatius Ou et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
A direct role for Met endocytosis in tumorigenesis
Carine Joffre et al.
NATURE CELL BIOLOGY (2011)
Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion
Yoshinari Asaoka et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas
Tatsuya Ozawa et al.
GENES & DEVELOPMENT (2010)
Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase
Qi Ma et al.
MOLECULAR CANCER (2010)
EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines
Dorine A. Bax et al.
CLINICAL CANCER RESEARCH (2009)
Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers
Ryoichi Onozato et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Phenotypic and genotypic characterization of orthotopic human glioma models and its relevance for the study of anti-glioma therapy
An Claes et al.
BRAIN PATHOLOGY (2008)
Expression and Mutational Analysis of MET in Human Solid Cancers
Patrick C. Ma et al.
GENES CHROMOSOMES & CANCER (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13R alpha 2, gp100 and TRP-2 for immunotherapy
Stephan Saikali et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Somatic mutations lead to an oncogenic deletion of Met in lung cancer
M Kong-Beltran et al.
CANCER RESEARCH (2006)
Functional expression and mutations of c-met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer
PC Ma et al.
CANCER RESEARCH (2005)
Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor
YW Zhang et al.
ONCOGENE (2005)
Met provides essential signals for liver regeneration
M Borowiak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor
E Gherardi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
CD44 is required for two consecutive steps in HGF/c-Met signaling
V Orian-Rousseau et al.
GENES & DEVELOPMENT (2002)
High expression of the Met receptor in prostate cancer metastasis to bone
BS Knudsen et al.
UROLOGY (2002)
The Semaphorin 4D receptor controls invasive growth by coupling with Met
S Giordano et al.
NATURE CELL BIOLOGY (2002)
Increasing the precision of comparative models with YASARA NOVA - a self-parameterizing force field
E Krieger et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2002)
The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met
A Petrelli et al.
NATURE (2002)
Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein
P Peschard et al.
MOLECULAR CELL (2001)
Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells
MJ Jo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
